Document Detail

Advances in the Current Treatment of Autoimmune Hepatitis.
MedLine Citation:
PMID:  22476586     Owner:  NLM     Status:  Publisher    
Current treatment strategies for autoimmune hepatitis are complicated by frequent relapse after drug withdrawal, medication intolerance, and refractory disease. The objective of this review is to describe advances that have improved treatment outcomes by defining the optimum objectives of initial therapy, managing relapse more effectively, identifying problematic patients early, and incorporating the new pharmacological interventions that have emerged as frontline and salvage therapies. Initial corticosteroid treatment should be continued until serum aminotransferase, γ-globulin, and immunoglobulin G levels are normal, and maintenance of this improvement for 3-8 months before liver tissue assessment. Improvement to normal liver tissue is the ideal histological result that justifies drug withdrawal, but it is achievable in only 22 % of patients. Minimum portal hepatitis, inactive cirrhosis, or minimally active cirrhosis is the most common treatment end point. Relapse after drug withdrawal warrants institution of a long-term maintenance regimen, preferably with azathioprine. Mathematical models can identify problematic adult patients early, as also can clinical phenotype (age ≤30 years and HLA DRB1*03), rapidity of treatment response (≤24 months), presence of antibodies to soluble liver antigen, and non-white ethnicity. The calcineurin inhibitors (cyclosporine and tacrolimus) can be effective in steroid-refractory disease; mycophenolate mofetil can be corticosteroid-sparing and effective for azathioprine intolerance; budesonide combined with azathioprine can be effective for treatment-naïve, non-cirrhotic patients. Standard treatment regimens for autoimmune hepatitis can be upgraded without adjustments that require major new expertise.
Albert J Czaja
Related Documents :
9167766 - Anemia associated with advanced prostatic adenocarcinoma: effects of recombinant human ...
7522646 - Management of peritoneal effusions with intracavitary mitoxantrone or bleomycin.
17617286 - Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: ...
10505566 - The use of twh catheters in capd patients: fourteen-year experience in technique, survi...
18679576 - Elective laparoscopic surgical management of recurrent and complicated sigmoid divertic...
19154456 - Failure of monotherapy in primary monosymptomatic enuresis: a combined desmopressin and...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-4-3
Journal Detail:
Title:  Digestive diseases and sciences     Volume:  -     ISSN:  1573-2568     ISO Abbreviation:  -     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-4-5     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7902782     Medline TA:  Dig Dis Sci     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street S.W., Rochester, MN, 55905, USA,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Esophageal Squamous Cell Carcinoma: Assessing Tumor Angiogenesis Using Multi-Slice CT Perfusion Imag...
Next Document:  Protective Effects of 3,4-Oxo-isopropylidene-Shikimic Acid on Experimental Colitis Induced by Trinit...